0000947871-22-000125.txt : 20220201 0000947871-22-000125.hdr.sgml : 20220201 20220201170901 ACCESSION NUMBER: 0000947871-22-000125 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220201 FILED AS OF DATE: 20220201 DATE AS OF CHANGE: 20220201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pillai Arun Kumar CENTRAL INDEX KEY: 0001717437 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 22580044 MAIL ADDRESS: STREET 1: #30, "GALAXY," 1ST MAIN STREET 2: J.P. NAGAR 3RD PHASE CITY: BANGALORE STATE: K7 ZIP: 560078 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 4 1 ownership.xml X0306 4 2022-02-01 0 0001649989 Outlook Therapeutics, Inc. OTLK 0001717437 Pillai Arun Kumar #30, 1ST MAIN J.P. NAGAR 3RD PHASE BANGALORE K7 560078 INDIA 1 0 1 0 Common Stock 2022-02-01 4 J 0 2500000 1.25 D 22982529 I See Footnote These securities are held of record by BioLexis Pte Ltd. ("BioLexis") and represent the number securities in which Arun Kumar Pillai ("Kumar"), a natural person, may be deemed to have an indirect pecuniary interest in by virtue of the relationships described herein. Tenshi Life Sciences Private Limited and Tenshi Life Sciences Pte. Limited (collectively, "Tenshi"), both private investment vehicles controlled by Kumar, are beneficial owners of BioLexis and Kumar is the holder of a controlling interest in Tenshi. Kumar disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. On January 31, 2022, GMS Pharma (Singapore) Pte. Limited ("GMS Pharma"), a private investment company and wholly-owned subsidiary of GMS Holdings, entered into a securities purchase agreement with each Tenshi entity, pursuant to which GMS Pharma purchased from Tenshi approximately 4.9% of the outstanding shares of BioLexis (the "Share Sale"), which corresponds to 2,500,000 shares of the Issuer held by BioLexis. The Share Sale closed on February 1, 2022. BioLexis has designated one representative to serve on the Issuer's board of directors. This report shall not be deemed an admission that Kumar is the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. /s/ Arun Pillai Kumar, By: Lawrence Kenyon, Attorney-in-Fact 2022-02-01